P&G Q1 FY2027 Earnings: $23.3B Sales, a $1.4B Commodity Warning, and Cash for Thorne

Procter & Gamble opened fiscal 2027 with net sales of $23.3 billion, up 4.0%, and organic sales up 4.0% on volume growth of 2.4% — while warning that commodity costs will be a $1.4 billion after-tax headwind this year and rewriting its sales guidance for the $3.8 billion Thorne acquisition, which closed October 1, the day after the quarter ended. Diluted EPS rose 1% to $1.97; core EPS rose 1% to $2.00.

The Headline Numbers​

P&G's fiscal year ends June 30, so the first quarter of fiscal 2027 is the three months ended September 30, 2026. Every figure below comes from the earnings release (8-K Exhibit 99.1) and the Form 8-K filed October 22, 2026, with annuals from the FY2026 and FY2025 10-Ks.

The shape of the quarter is a staples company growing the top line while the cost line grows faster. Sales rose $890 million; cost of products sold rose $791 million, up 7% — nearly nine-tenths of the sales gain went straight into product costs. Gross profit grew just 1%, and the 160-basis-point margin decline is the number the rest of the release is spent explaining. Below that, the company held the line impressively: SG&A was essentially flat in dollars and fell 90 basis points as a share of sales, so operating income still grew 1%. Net income attributable to P&G was flat at $4,731 million, and the 1% EPS growth is the buyback doing its quiet work — diluted shares fell from 2,436.8 million to 2,407.2 million.

The GAAP-to-core bridge is small this quarter, which is itself informative after a year of heavy restructuring charges: $100 million pre-tax of incremental restructuring ($44 million in cost of products sold, $54 million in SG&A, $2 million in other non-operating income) becomes $80 million after tax, or $0.03 a share — the distance between $1.97 and $2.00. Currency-neutral core EPS was flat at $1.99, so the "growth" this quarter is, on a currency-neutral core basis, zero. That is an honest quarter, not a great one.

Revenue Deep Dive​

All five segments grew reported sales, and the mix of that growth is healthier than the headline suggests: company-wide volume rose 2.4%, mix added 1.1 points, pricing added 0.4 points, and foreign exchange was neutral.

Beauty (+6.4% reported, +5.4% organic) was the fastest grower. Hair Care grew mid-single digits on "innovation-based pricing in North America and Latin America, favorable product mix and an increase in unit volume," while Personal Care rode volume growth in Greater China and Europe. Note the tension in the profit line, though: Beauty earnings before tax grew only 1% and segment net earnings fell 1% — the reinvestment is heaviest where the growth is fastest.

Grooming (+4.0%, +4.5% organic) is the pricing-power showcase of the quarter: volume actually fell 0.4%, but price added 3.5 points, "driven by innovation-based pricing, primarily in North America and IMETA, and favorable product mix." When a razor business can shrink units and still grow the top line 4%, the brand is doing the work.

Health Care (+3.1%, +2.7% organic) paired the weakest volume in the company (−2.9%) with the strongest profit growth (+10% EBT). Oral Care and Personal Health Care both traded volume for "premium product mix" and higher pricing. This is the segment Thorne will join, and the quarter shows why P&G wants more of it: the earnings yield per sales dollar is the highest in the portfolio.

Fabric & Home Care (+4.2%, +4.8% organic), the largest segment at $8.2 billion, is the mirror image of Grooming: volume up 4.3% in North America and Europe, pricing down 0.3%. Tide and Ariel are winning on tubs moved, not price tags raised — exactly what you'd expect in a quarter where the company concedes "pricing had a minor positive impact on sales."

Baby, Feminine & Family Care (+2.9%, +3.0% organic) is the soft spot: the only segment whose earnings fell (−4% on both EBT and net). Baby Care grew volume "primarily in Greater China and North America" but cut price in North America; Family Care's volume gain was "partially offset by merchandising investments." When pricing goes negative to hold volume, margins go with it.

The management-signal scan of the release finds no demand-cycle language at all — no "robust demand," no supply constraints, no upcycle talk. For a consumer-staples company that is the normal state of the world, not a signal change. The operative phrases are "innovation-based pricing" (cited in three of five segments) and volume-led growth. The bull case for the quarter is that 2.4 points of the 4.0% growth came from units; the bear case is that pricing power, ex-Grooming, is nearly exhausted.

The Margin Story​

(Note the seasonal pattern: Q1 is structurally P&G's highest-margin quarter, so the right comparison is year-over-year, not against the full-year average.)

The release gives an unusually complete 160-basis-point gross-margin walk, and it is worth reading mechanically: −140 bps commodities, −140 bps product reinvestments, −50 bps unfavorable mix, −10 bps other, offset by +120 bps productivity savings, +50 bps tariff impact (lower costs plus recognized recoveries), and +20 bps pricing. Two things stand out. First, commodities alone (−140 bps) explain nearly the whole decline — the $1.4 billion full-year commodity warning in the guidance section is this quarter's margin walk annualized. Second, tariffs were a tailwind this quarter (+50 bps from lower costs and recoveries), a reminder that P&G's tariff exposure cuts both ways as duties and refunds move through inventory.

SG&A is the genuine bright spot: down 90 bps as a share of sales on "130 basis points of productivity savings and 100 basis points of net sales growth leverage, partially offset by 120 basis points of reinvestments." Nominal SG&A rose just $18 million on $890 million of new sales. With advertising running around $9 billion a year, holding the total marketing-and-overhead line flat while growing volumes 2.4% is the productivity plan visibly working — headcount is down 4% year-over-year to about 104,000 employees under the restructuring program.

Net margin of 20.3% — one dollar of profit in every five of sales — remains the envy of consumer staples. But the direction is down 90 bps year-over-year, and every point of the decline traces to the cost of what goes into the box, not the cost of running the company.

The One Big Question: What Does $3.8B of Thorne Buy?​

In August, P&G agreed to acquire Thorne, a premium wellness and supplement brand in vitamins, minerals and supplements, for $3.8 billion; the deal closed October 1, the day after this quarter ended. Thorne therefore appears nowhere in these numbers — and everywhere in the guidance. P&G raised its all-in fiscal-2027 sales growth outlook to 2–4% to reflect the acquisition while holding organic growth at 1–3%, which tells you Thorne is worth roughly a point of growth on an $87 billion base.

The balance sheet shows the company prefunded the deal. Cash jumped $5.4 billion in the quarter, from $9,942 million to $15,365 million — and debt due within one year jumped $5.7 billion, from $11,296 million to $17,028 million, on net additions to short-term debt of $5,758 million. P&G drew commercial paper to hold cash across the quarter-end, then wrote the Thorne check on October 1. Net debt actually fell $636 million in the quarter (to $23,560 million), because operating cash flow of $5.8 billion covered both the dividend, the buyback, and then some. This is a company that can swallow a $3.8 billion acquisition without moving its leverage a hair — total debt ended the quarter at $38,925 million against $133,132 million of assets.

The strategic question is whether wellness supplements earn P&G-style returns. Health Care is already the highest-margin segment, and Thorne's premium positioning fits the "superior products at a superior value" strategy the CEO letter keeps returning to. But $3.8 billion against a Health Care segment doing $12.5 billion in annual sales is a ~30% bet on one brand in a category P&G has never led — vitamins and supplements are a long way from Crest and Vicks. The bear case writes itself: consumer-health M&A has a poor industry record, and the $1.3 billion Gillette impairment of FY2024 is a fresh reminder that P&G overpays sometimes too. The bull case is distribution: whatever Thorne sells today, it has never been sold through P&G's shelf space, where Walmart alone accounts for 16% of company sales.

Watch two lines over the next three quarters: Health Care organic growth (does Thorne accelerate it?) and goodwill, which should step up by roughly the purchase price less Thorne's tangible book when the Q2 balance sheet lands. If goodwill jumps and segment growth doesn't, the market will do the math.

Tracking a $133B Company in Plain Text​

A consumer-staples giant is exactly the kind of company double-entry bookkeeping clarifies: every dollar of the $890 million sales gain has to land somewhere, and the ledger forces the margin walk to reconcile rather than merely narrate. This post's figures come from a public Beancount ledger covering FY2025 through Q1 FY2027 — read how we model every company for the conventions shared across the fleet.

Here is the quarter's income statement as the ledger records it (income is negative because it is a credit; the check comment proves the transaction sums to zero):

; FY2027Q1 Income Statement — first quarter ended September 30, 2026
; Check: −23276 + 11678 + 5661 − 309 + 223 + 26 − 1 + 1267 + 4731 = 0 ✓
2026-09-30 * "The Procter & Gamble Company" "FY2027Q1 Income Statement"
  Income:Revenue                              -23276 MUSD
  Expenses:CostOfRevenue                       11678 MUSD
  Expenses:SellingGeneralAdministrative          5661 MUSD
  Income:OtherNet                                -309 MUSD
  Expenses:OtherNet                               223 MUSD
  Expenses:OtherNet                                26 MUSD
  Expenses:OtherNet                                -1 MUSD
  Expenses:IncomeTax                             1267 MUSD
  Equity:Adjustments                             4731 MUSD

(The −1 MUSD posting is disclosed rounding: the filed lines foot to $4,756 million while the release states net earnings of $4,757 million — the release itself warns that columns may not add.)

The balance-sheet number that tells the quarter's story is the matched pair: cash $9,942M → $15,365M against short-term debt $11,296M → $17,028M. Strip those two lines out and the balance sheet barely moved — goodwill, intangibles, receivables and inventory all sit within a few percent of June. The quarter's entire balance-sheet drama is P&G staging $5-plus billion of liquidity for October 1.

The Multi-Year Arc​

The ledger opens at FY2025 — a first-quarter bootstrap pairs two audited annuals with the new quarter — and even two years show the P&G formula clearly: mid-single-digit sales growth, twenty-plus percent operating margins, and cash returned faster than most companies earn it.

FY2026 deserves a footnote in any multi-year read: reported operating income fell 3.4% that year while sales grew 3.3%, because the company absorbed $903 million after tax of restructuring charges under its two-year, $1.5–2.0 billion portfolio and productivity plan — and still grew core EPS 1% to $6.89 while booking a $261 million after-tax gain dissolving the Glad joint venture. The plan promises up to 7,000 fewer non-manufacturing roles by end of FY2027; with "over half" of the cost already taken in FY2026, this fiscal year should show the savings side of that trade. Q1's flat SG&A is the first installment.

The compounding story, such as it is at this scale, runs through the share count and the dividend, not the top line: sales compounded about 2% across these two years while diluted EPS compounded a touch faster and the quarterly dividend rose from $1.0568 to $1.0885. Nobody buys P&G for growth; they buy it because $16 billion of annual net income funds $10-plus billion of dividends with room for $5 billion of buybacks, every year, through commodity cycles.

The Verdict: Bull vs. Bear​

Bull Case

• Volume-led 4% growth is the real thing. Two-thirds of the quarter's growth came from units (+2.4%), not price — Fabric Care volumes up in North America and Europe, Baby Care volumes up in Greater China — which is demand, not inflation accounting.
• SG&A leverage proves the restructuring is working. Flat overhead dollars on 4% sales growth, headcount down 4%, and the productivity plan's savings arriving on schedule with the cost mostly behind.
• The balance sheet absorbs Thorne standing still. $15.4 billion of cash, net debt down in the quarter, and a $3.8 billion deal funded from commercial paper — leverage is a non-issue.
• Cash conversion is elite. $5.8 billion of operating cash flow, 93% free-cash-flow productivity, $3.9 billion returned in a single quarter — the dividend machine is intact.
• Innovation pricing is spreading. Three of five segments cite "innovation-based pricing," and Grooming grew sales 4% while selling fewer units — brand power that compounds.

Bear Case

• The $1.4 billion commodity headwind is already here. Q1 gross margin fell 160 bps with commodities costing 140 bps; the full-year warning prices an 11% drag on core EPS growth that productivity must fully offset just to stand still.
• Currency-neutral core EPS was flat. Strip FX and restructuring and the company earned $1.99 versus $1.99 — all of the quarter's "growth" is buybacks and one-offs, and the release's demand language is conspicuously absent.
• Pricing power is nearly gone. Company-wide price contributed 0.4 points; two segments cut price outright. If commodities don't cooperate, P&G must choose between volume and margin — Baby Care already chose volume.
• Thorne is an expensive experiment. $3.8 billion — 30% of Health Care's annual sales — for a supplements brand in a category with a poor M&A record, closing into a deteriorating consumer. Goodwill will jump in Q2; growth must follow.
• The consumer is trading within the portfolio, not up. Mix added 1.1 points overall but cost 50 bps of gross margin — shoppers are buying more P&G, but cheaper P&G.

Our Take: This is a well-executed quarter inside a difficult year. P&G grew volumes, held overhead flat, converted cash at 93%, and staged the Thorne acquisition without stressing the balance sheet — that is operational excellence by any standard. But the commodity cycle, not management, will decide FY2027: with an $0.79-per-share headwind stack and pricing power fading, the maintained core-EPS guide of up to 3% growth requires everything to go right from here. Hold the dividend, watch Health Care. If Thorne accelerates that segment by spring, the premium paid will look like foresight; if Q2 brings another price-cut quarter in Baby and Family Care, the consumer is telling you something. The ledger will show it first — in units, not adjectives.